Home › Funds › Nextech Invest Ltd. › CRVS
Nextech Invest Ltd. position in CRVS
CORVUS PHARMACEUTICALS I · Health Care
Nextech Invest Ltd. reported holding 450,000 shares of CRVS (CORVUS PHARMACEUTICALS I) in its Q2 2026 13F filing — a position valued at US$6.7M, representing 0.32% of its reported portfolio and ranking #13 among its reported holdings. Nextech Invest Ltd. has disclosed CRVS holdings in 2 of the last 2 reported quarters, going back to Q1 2026.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Nextech Invest Ltd.'s CRVS position evolved
Nextech Invest Ltd. first disclosed a stake in CRVS in Q1 2026 at 450,000 shares (US$6.6M). The position peaked in Q2 2026 at 450,000 shares, worth US$6.7M. Across 2 filings, Nextech Invest Ltd. held the position steady without any share-count change. The most recent filing (Q2 2026) shows 450,000 shares valued at US$6.7M.
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q1 2026 | 450.00K | $6.58M | New |
| Q2 2026 | 450.00K | $6.72M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About CRVS and 13F data
CRVS (CORVUS PHARMACEUTICALS I) is a Health Care company. 72 other funds we track also report a position in CRVS — the largest reported positions include ORBIMED ADVISORS LLC (US$107.0M), ADAMS STREET PARTNERS LLC (US$48.9M), Vivo Capital, LLC (US$41.9M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding CRVS
- ORBIMED ADVISORS LLC 7.17M sh · $107.05M · Q2 2026
- ADAMS STREET PARTNERS LLC 3.28M sh · $48.94M · Q2 2026
- Vivo Capital, LLC 2.81M sh · $41.92M · Q2 2026
- PERCEPTIVE ADVISORS LLC 2.67M sh · $39.85M · Q2 2026
- Deep Track Capital, LP 2.49M sh · $37.23M · Q2 2026
- BRAIDWELL LP 2.13M sh · $31.77M · Q2 2026
- Foresite Capital Management VI LLC 1.83M sh · $27.36M · Q2 2026
- Boxer Capital Management, LLC 1.10M sh · $16.43M · Q2 2026
- Catalio Capital Management, LP 1.08M sh · $16.15M · Q2 2026
- Eversept Partners, LP 747.99K sh · $11.18M · Q2 2026
- DCF Advisers, LLC 637.50K sh · $9.52M · Q2 2026
- Blue Owl Capital Holdings LP 608.60K sh · $9.09M · Q2 2026
More on Nextech Invest Ltd.
FAQ
How long has Nextech Invest Ltd. held CRVS?
Nextech Invest Ltd. has disclosed CRVS holdings in 2 of the last 2 reported quarters, going back to Q1 2026.
What is Nextech Invest Ltd.'s current position in CRVS?
As of Q2 2026, Nextech Invest Ltd. holds 450.00K shares of CRVS (CORVUS PHARMACEUTICALS I), valued at $6.72M, representing 0.32% of its reported portfolio and ranking #13.
Has Nextech Invest Ltd. been buying or selling CRVS?
In the latest 13F filing (Q2 2026), Nextech Invest Ltd. held unchanged its position in CRVS. The position peaked in Q2 2026 at 450.00K shares.
Which other funds hold CRVS?
Other major institutional holders of CRVS include ORBIMED ADVISORS LLC, ADAMS STREET PARTNERS LLC, Vivo Capital, LLC, among 72 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.